Does Antithrombotic Therapy Influence Residual Thrombus after Thrombolysis of Platelet-Rich Thrombus?: Effects of Recombinant Hirudin, Heparin, or Aspirin

Circulation

Volumn 93, Issue 4, 1996, Pages 792-799

  Mruk, Jozef S ^a   Zoldhelyi, Pierre ^a   Webster, Mark W I ^a   Heras, Magda ^a   Grill, Diane E ^a   Holmes Jr , David R ^a   Fuster, Valentin ^b   Chesebro, James H ^a,b  

^a MAYO CLINIC   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Fibrin; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; DESULFATOHIRUDIN; HEPARIN; LEPIRUDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY INJURY; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYTIC THERAPY; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBUS;

ANIMALS; ASPIRIN; BLOOD PLATELETS; CAROTID ARTERIES; DRUG THERAPY, COMBINATION; FIBRIN; FIBRINOLYTIC AGENTS; HEMOSTASIS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; RECOMBINANT PROTEINS; SWINE; THROMBOSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030054124     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.4.792     Document Type: Article

References (73)

1. Gruppo Italiano Per Lo Studio Della Streptochinasi Nell-Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
2. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs antistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1993;339:753-770.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
4. The GUSTO Angiographic Investigators. An angiographic study within the global randomized trial of aggressive versus standard thrombolytic strategies in patients with acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
5. Marder VJ, Sherry S. Thrombolytic therapy: current status (two parts). N Engl J Med. 1988;318:1512-1520, 1585-1595.
6. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hills D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76: 142-154.
7. Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med. 1987;317:1613-1618.
8. Winters KJ, Santoro SA, Miletich JP, Eisenberg PR. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation. 1991;84:1552-1560.
9. 2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res. 1989;65:83-94.
10. Eisenberg PR, Sherman L, Rich M, Schwartz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 1986;7:1255-1262.
11. Chesebro JH, Fuster V. Dynamic thrombosis and thrombolysis: role of antithrombins. Circulation. 1991;83:1815-1817.
12. Meyer BJ, Badimon JJ, Mailhac A, Fernandez-Ortiz A, Chesebro JH, Fuster V, Badimon L. Inhibition of growth of thrombus on fresh mural thrombus: targeting optimal therapy. Circulation. 1994; 90:2432-2438.
13. Lee DC, Mann KD. Activation/inactivation of human factor V by plasmin. Blood. 1989;73:185-190.
14. Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science. 1945;101:520-521.
15. Bloom AL. The release of thrombin from fibrin by fibrinolysin. Br J Haemost. 1962;8:129-133.
16. Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood. 1989;74:1025-1030.
17. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
18. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433-1437.
19. Mruk JS, Chesebro JH, Webster WMI. Platelet aggregation and interaction with the coagulation system: implications for antithrombotic therapy in arterial thrombosis. J Coron Artery Dis. 1990; 1:149-158.
20. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci U S A. 1988;85: 3184-3188.
21. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665.
22. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin and placebo during arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1484.
23. 2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation. 1992;86:1993-1999.
24. Collen D, Matsuo O, Stassen JM, Kettner C, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med. 1982;99:76-83.
25. Jang I-K, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation. 1990;81:219-225.
26. Cercek B, Lew AS, Hod H, Yano J, Reddy NKNR Ganz. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation. 1986;74:583-587.
27. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3α-diphenyl-glycouril. Biochem Biophys Res Commun. 1978;80:849-857.
28. Dewanjee MK. Methods of assessment of thrombosis in vivo. Ann N Y Acad Sci. 1987;516:541-571.
29. Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: natural history of the pathophysiologic response to injury in a pig model. Circ Res. 1985;57:105-112.
30. Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. Circulation. 1988;78:712-716.
31. Andrew M, Ofosu F, Schmidt B, Brooker L, Hirsh J, Buchanan MR. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res. 1988;52:517-527.
32. Bochner F, Siebert DM, Rodgers SE, McIntosh GH, James MJ, Lloyd JV. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Thromb Haemost. 1989;61:211-216.
33. Galvez A, Badimon L, Badimon JJ, Fuster V. Electric aggregometry in whole blood from human pig and rabbit. Thromb Haemost. 1986;56:128-132.
34. Fears R, Ferres H, Greenwood H. An investigation of methods to prevent fibrinogen degradation during processing of plasma samples containing the fibrinolytic agents, APSAC and t-PA. Fibrinolysis. 1989;3:45-49.
35. Stump DC, Topol EJ, Chen AB, Hopkins A, Collen D. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. Thromb Haemost. 1988;59:133-137.
36. Jacobsson K. Studies on the determination of fibrinogen in human blood plasma. Scand J Clin Lab Invest. 1955;7:1-54.
37. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reagent. J Biol Chem. 1949;177:751.
38. Doumas BT, Bayse DD, Carter RJ, Peters T Jr, Schaffer R. A candidate reference method for determination of total protein in serum, I: development and validation. Clin Chem. 1981;27:1642-1650.
39. Haverkate F, Brakman P. Fibrin plate assay. Prog Chem Fibrinol Thromb. 1975;1:151-159.
40. Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemost. 1979;41:365-383.
41. Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents. Haemostasis. 1983;13:301-315.
42. Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemost. 1985;53:134-136.
43. Rånby M. On the properties of the international standards for tissue plasminogen activator. Thromb Haemost. 1990;63:139. Letter.
44. Hassinger NL, McBane RD, Mruk JS, Zoldhelyi P, Grill DE, Chesebro JH. All thrombin inhibitors are not created equal: the paradox of anticoagulant versus antithrombotic efficacy. Thromb Haemost. 1993;69:888.
45. GUSTO IIa Investigators. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
46. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
47. Rogers WJ, Babb JD, Baim DS, Chesebro JH, Gore JM, Roberts R, Williams DO, Frederick M, Passamani ER, Braunwald E, for the TIMI II Investigators. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. J Am Coll Cardiol. 1991;17:1007-1016.
48. Wysokinski WE, McBane RD, Hassinger ML, Stewart ML, Chesebro JH, Owen WG. 'Dethrombosis': effect of thrombin inhibition on thrombus propagation and maintenance. Thromb Haemost. 1993; 69:692. Abstract.
49. Zoldhelyi P, Chesebro JH, Owen WG. Hirudin as a molecular probe for thrombin in vitro and during systemic coagulation in the pig. Proc Natl Acad Sci USA. 1993;90:1819-1823.
50. Weitz JI, Hudoba M. Mechanism by which clot-bound thrombin is protected from inactivation by fluid-phase inhibitors. Circulation. 1992;86(suppl I):I-413. Abstract.
51. Bock PE, Luscombe M, Marshall SE, Pepper DS, Holbrook JJ. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J. 1980;191;769-776.
52. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A. 1989;86:3619-3623.
53. Hogg PJ, Jackson CM. Heparin promotes the binding of thrombin to fibrin polymer: quantitative characterization of a thrombin-fibrin polymer-heparin ternary complex. J Biol Chem. 1990;265:241-247.
54. Hogg PJ, Jackson CM. Formation of a ternary complex between thrombin, fibrin monomer, and heparin influences the action of thrombin on its substrates. J Biol Chem. 1990;265:248-255.
55. Markwardt F, Stürzebecher J, Glusa E. Antithrombin effects of native and recombinant hirudins. Biomed Biochim Acta. 1990;49: 399-404.
56. Cannon CP, McCabe CH, Henry TD, Schweiger M, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol. 1994;23: 993-1003.
57. Arnout J, Simoons M, de Bono D, Rapold JH, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 1992;20:513-519.
58. Zeymer U, Jessel A, Neuhaus K-L. Hirudin as conjunctive therapy in patients with thrombolysis for acute myocardial infarction produced stable prolongation of ACT and APTT. Circulation. 1993; 88(suppl I):I-201. Abstract.
59. Antman EM. Antiplatelet/Antithrombotic Agents [audiotape or videotape]. Dallas, Tex: American Heart Association Inc; 1995. Presented at the 68th Scientific Sessions of the American Heart Association; November 13, 1995; Anaheim, Calif.
60. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056.
61. Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol. 1992;19:671-677.
62. Chesebro JH, Webster MWI, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ. Antithrombolytic therapy in the progression of coronary artery disease: antiplatelet versus antithrombins. Circulation. 1992;86(suppl III):III-100-III-110.
63. Susawa T, Yui Y, Hattori R, Takatsu Y, Yui N, Takahashi M, Aoyama T, Murohara T, Shirotani M, Kawai C. Enhancement of coronary thrombolysis with plasminogen proactivator by pretreatment with heparin. Jpn Circ J. 1987;52:72-78.
64. Cercek B, Lew AS, Satoh Y, Isojima K, Laramee P, Yano J, Yano J, Reddy KNN, Masddahi J, Ganz W. Heparin enhances experimental thrombolysis by preventing new fibrin deposition. Circulation. 1985; 72(suppl III):III-194. Abstract.
65. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):II-38-II-46.
66. Friedman MF, Van der Bovenkamp EJ. The pathogenesis of a coronary thrombus. Am J Pathol. 1966;48:19-44.
67. Fernandez-Ortiz A, Badimon JJ, Folk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23: 1562-1569.
68. Jang I, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation. 1990;81:219-225.
69. Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest. 1987;79:1749-1755.
70. Markwardt F, Kaiser B, Novak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res. 1989;54:377-388.
71. Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton JW, Blajchman MA. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochem J. 1989;257:143-150.
72. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Fuster V. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. Arterioscler Thromb. 1992;12:250-255.
73. Niewiarowski S, Latallo Z. Comparative studies of the fibrinolytic system of sera of various vertebrates. Thromb Diath Haemosrrh. 1959;3:404-417.